Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 19Other 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Paclitaxel 35Bevacizumab 31Carboplatin 29pembrolizumab 25Specimen Handling 20Magnetic Resonance Spectroscopy 18olaparib 16Cisplatin 15liposomal doxorubicin 13Taxes 12Immunoglobulin G 11Gemcitabine 11Disulfides 11Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 8fludarabine 7Doxorubicin 7mirvetuximab soravtansine 6niraparib 5Radiation 5Oxaliplatin 5Fulvestrant 5Fluorouracil 5trastuzumab deruxtecan 4durvalumab 4cediranib 4Platinum 4Megestrol Acetate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anastrozole × Gynecologic × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡